EUVIMEDDescobrir EUVIMED
Open access · CC BY-NC-ND 4.0

Caught in a loop: Glucagon-like peptide-1 agonists and weight loss technology as a commercial determinant of health

Andrea Bombak, Emily Paul, Braeden Martin, Ashley Morehouse, Taylor McAulay, Megan Warin, Natalie Riediger

Journal of Critical Public Health · 2026-11-18

DOI: 10.55016/mxhey898 ↗

At a glance

Journal article in Journal of Critical Public Health, published online on 2026-11-18. Written by Andrea Bombak and 6 co-authors. The full text is freely available (open access, CC BY-NC-ND 4.0).

ResumoDados bibliográficosCiteRelated studies

Abstract (original language)

We examined how companies that manufacture weight loss pharmaceuticals, Glucagon-like peptide-1 agonists, along with the non-profits they sponsor and their public facing websites, operate as commercial determinants of health through the discourses they produce online. Data were extracted from organization websites and uploaded into NVivo 15 for multimodal critical discourse analysis. Discourses identified were not new but recursively constructed ‘obesity’ through a medicalized discourse grounded in scientific authority, as diseased, and needing treatment, which reproduces discourses of other weight loss ‘cures’. The Body Mass Index was presented as an objective, but limited, metric to classify bodies, rendering health risk quantifiable. Structural determinants of health were acknowledged but absorbed into a medicalized framework. Across all sources, healthcare professionals were positioned as saviours, guiding individuals toward successful outcomes. A final discourse, present only on pharmaceutical and non-profit sites, framed commercial pharmaceutical intervention as necessary to ease the economic burden of ‘obesity’ on public services. In conclusion, these websites contribute to the pharmaceuticalization of weight and the commercialization of bodily dissatisfaction and health. Although they attempt to project themselves as anti-stigmatizing, these discourses remain highly individualized, clinically focused, and reproduce and reinforce weight-based stereotypes.

Cite

APA

Bombak, A., Paul, E., Martin, B., Morehouse, A., McAulay, T., Warin, M., & Riediger, N. (2026). Caught in a loop: Glucagon-like peptide-1 agonists and weight loss technology as a commercial determinant of health. Journal of Critical Public Health. https://doi.org/10.55016/mxhey898

Vancouver

Bombak A, Paul E, Martin B, Morehouse A, McAulay T, Warin M, et al. Caught in a loop: Glucagon-like peptide-1 agonists and weight loss technology as a commercial determinant of health. Journal of Critical Public Health. 2026. doi:10.55016/mxhey898

BibTeX
@article{Bombak2026,
  author = {Bombak, Andrea and Paul, Emily and Martin, Braeden and Morehouse, Ashley and McAulay, Taylor and Warin, Megan and Riediger, Natalie},
  title = {Caught in a loop: Glucagon-like peptide-1 agonists and weight loss technology as a commercial determinant of health},
  journal = {Journal of Critical Public Health},
  year = {2026},
  doi = {10.55016/mxhey898}
}
Start for free →